Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Defining therapeutic chimerism thresholds for comprehensive sickle cell disease correction in the townes mouse model

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDeAnna DiazFCFrançois Christen

Discussion

Loading...

Member takes

Overview

This study demonstrates the relationship between hematopoietic stem cell chimerism and sickle cell disease outcomes, suggesting gene therapy refinements may alleviate complications.

Key Points

  • To determine critical thresholds of hematopoietic stem cell chimerism necessary for alleviating symptoms of sickle cell disease.
  • Utilized Townes SCD mouse model to create mixed hematopoietic chimeras.
  • Transplanted varying ratios of SCD:wild-type donor hematopoietic stem cells.
  • Monitored chimerism, HbS levels, and sickle RBC proportions in peripheral blood and myeloid cells.
  • 2-3% wild-type HSC chimerism reduced sickle RBC proportions and HbS by 50%.
  • Near-complete sickle RBC elimination occurred at 10-30% wild-type HSC chimerism levels.
  • Hemolysis and extramedullary hematopoiesis improved significantly at above 30% HSC chimerism.

Cite This Study

Diaz et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236daebhttps://doi.org/10.1182/blood-2025-4700
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Non-genotoxic conditioning to increase donor chimerism levels in a mismatched murine transplant model for sickle cell disease2025
  2. 2Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease2026
  3. 3Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease2026
  4. 4The New Era of Curative Therapies for Sickle Cell Disease: A Comprehensive Review of Allogeneic Transplantation and Autologous Gene Therapy2026
  5. 5Impact of pre-transplant bone marrow cellularity and fibrosis on post-transplant outcomes in sickle cell disease2025